The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

被引：0
|
作者：
Uzma Khan
Helena Huerga
Aamir J. Khan
Carole D. Mitnick
Catherine Hewison
Francis Varaine
Mathieu Bastard
Michael Rich
Molly F. Franke
Sidney Atwood
Palwasha Y. Khan
Kwonjune J. Seung
机构：
[1] Interactive Research and Development (IRD),Field Epidemiology Department
[2] Epicentre,Department of Global Health and Social Medicine
[3] Interactive Research and Development (IRD) Global,Medical Department
[4] Harvard Medical School,Division of Global Health Equity
[5] Médecins Sans Frontières,undefined
[6] Partners In Health,undefined
[7] Brigham and Women’s Hospital,undefined
来源：
BMC Infectious Diseases | / 19卷
关键词：
MDR-TB; Bedaquiline; Delamanid; Safety; Efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] MDR-TB TREATMENT UPDATE
    Wasserman, Sean
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 130 : S49 - S49
  • [22] Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
    Sweeney, Sedona
    Gomez, Gabriela
    Kitson, Nichola
    Sinha, Animesh
    Yatskevich, Natalia
    Staples, Suzanne
    Moodliar, Ronelle
    Motlhako, Sharon
    Maloma, Matshepo
    Rassool, Mohammed
    Ngubane, Nosipho
    Ndlovu, Ella
    Nyang'wa, Bern-Thomas
    BMJ OPEN, 2020, 10 (10):
  • [23] Surveillance for MDR-TB: is there an obligation to ensure treatment for individuals identified with MDR-TB?
    Edginton, M. E.
    Miller, D. L.
    Burney, P.
    El Sony, A. I.
    Lwilla, F. I.
    O'Brien, R.
    Roldan, M. B.
    Roldan, A.
    Srinath, S.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (09) : 1094 - 1096
  • [24] Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study
    Gao, M.
    Gao, J.
    Xie, L.
    Wu, G.
    Chen, W.
    Chen, Y.
    Pei, Y.
    Li, G.
    Liu, Y.
    Shu, W.
    Fan, L.
    Wu, Q.
    Du, J.
    Chen, X.
    Tang, P.
    Xiong, Y.
    Li, M.
    Cai, Q.
    Jin, L.
    Mei, Z.
    Pang, Y.
    Li, L.
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (04) : 597 - 602
  • [25] Treatment failure and MDR-TB
    Spinaci, S
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 1999, 3 (05) : 365 - 365
  • [26] Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea
    Mok, Jeongha
    Kang, Hyungseok
    Koh, Won-Jung
    Jhun, Byung Woo
    Yim, Jae-Joon
    Kwak, Nakwon
    Lee, Taehoon
    Kang, Bohyoung
    Jeon, Doosoo
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54 (05)
  • [27] Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB
    Khan, Faiz Ahmad
    Gelmanova, Irina Y.
    Franke, Molly F.
    Atwood, Sidney
    Zemlyanaya, Nataliya A.
    Unakova, Irina A.
    Andreev, Yevgeniy G.
    Berezina, Valentina I.
    Pavlova, Vera E.
    Shin, Sonya S.
    Yedilbayev, Askar B.
    Becerra, Mercedes C.
    Keshavjee, Salmaan
    CLINICAL INFECTIOUS DISEASES, 2016, 63 (02) : 214 - 220
  • [28] Experience of treatment Pre-XDR and XDR-TB/HIV co-infection with bedaquiline and delamanid containing regimens in Georgia
    Kiria, Nana
    Avaliani, Zaza
    Bolokadze, Natalia
    Kiria, Nino
    Mikiashvili, Lali
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [29] Linezolid in the treatment of MDR-TB: a retrospective clinical study
    Xu, H-B.
    Jiang, R-H.
    Li, L.
    Xiao, H-P.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (03) : 358 - 363
  • [30] Treatment of MDR-TB: is hepatotoxicity a problem?
    Loddenkemper, Robert
    Schaberg, Tom
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (05) : 571 - 571
12345